Analyst Ratings For C4X Discovery Holdings PLC (LON:C4XD)
Today, Panmure Gordon initiated coverage on C4X Discovery Holdings PLC (LON:C4XD) with a Buy with a price target of GBX 129.
There are 1 buy rating on the stock.
The current consensus rating on C4X Discovery Holdings PLC (LON:C4XD) is Buy (Score: 3.00) with a consensus target price of GBX 129 per share, a potential .
Some recent analyst ratings include
- 2/21/2017-Panmure Gordon initiated coverage with a Buy rating.
About C4X Discovery Holdings PLC (LON:C4XD)
C4X Discovery Holdings PLC is a drug discovery and development company. The Company is engaged in the provision of new technologies for drug discovery process for small molecule therapies. The Company offers platform that enables to develop therapies to treat a range of diseases, such as addiction through Orexin-1 (Ox-1); chronic obstructive pulmonary disease (COPD) and inflammation through NRF-2 pathway; diabetes through GPR142 and GLP-1, and inflammation and autoimmune diseases through Interleukin 17 (IL-17). The Company offers two software platforms: Taxonomy3 and Conformetrix. It offers a software platform for determining three-dimensional (3D) shapes of drug molecules from in-vitro data and this enables the design and discovery of drugs for diseases across various therapeutic areas. The Company’s Taxonomy3 is a human genetics analysis platform that utilizes a mathematical approach for discovery and validation of drug targets for the treatment of various diseases.
Recent Trading Activity for C4X Discovery Holdings PLC (LON:C4XD)
Shares of C4X Discovery Holdings PLC closed the previous trading session at 90.00 down -2.50 -2.70% with 0 shares trading hands.